Can you provide background, including dosing and units of each component, for the two fixed ratio, combination, insulin-plus-GLP-1 receptor agonist formulations likely to be approved?

Can you provide background, including dosing and units of each component, for the two fixed ratio, combination, insulin-plus-GLP-1 receptor agonist formulations likely to be approved?

Can you provide some background, including dosing and units of each component, for the two fixed ratio, combination, insulin-plus-GLP-1 receptor agonist formulations that have been investigated and are likely to be approved?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Juan Frias, FACE, MD

Juan Frias, FACE, MD

Clinical Assistant Professor of Medicine
University of California
San Diego, California
Chief Medical Officer
National Research Institute
Los Angeles, California